Serum Relaxin-3 and Irisin Levels in Children with Autism Spectrum Disorder: Comparison with Healthy Controls
Israel Journal of Psychiatry, cilt.59, sa.1, ss.42-46, 2022 (Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 59 Sayı: 1
- Basım Tarihi: 2022
- Dergi Adı: Israel Journal of Psychiatry
- Derginin Tarandığı İndeksler: Scopus
- Sayfa Sayıları: ss.42-46
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Objective: The incidence of Autism Spectrum Disorder (ASD) has increased in recent years. Genetic, biological and environmental factors play a role in its etiopathogenesis. The relationship between ASD and neuropeptides, one of the biological factors, is being increasingly investigated. This study aims to compare serum relaxin-3 and irisin levels of ASD cases with healthy controls. Methods: This prospective case-control study involves a total of 68 children: 38 ASD diagnosed patients as the case group and 30 as the control group. Serum relaxin-3 and irisin levels were measured using the enzyme-linked immunosorbent assay technique. Results: Serum relaxin-3 and irisin levels were found to be lower in the case group than in the control group. However, a statistically significant difference between groups was found only for serum irisin levels. The cut-off value for serum irisin level was determined as 3.5 ng/ml. Conclusion: Irisin may play a potential role in the etiopathogenesis of ASD. A more extensive series of studies are needed in order to establish the use of this biomarker in the diagnosis and management of ASD.